TriSalus jumps after FDA clears liver treatment device

TriSalus Life Sciences

23/09/2026 14:43

Updates
** Shares of cancer therapy firm TriSalus TLSI.O rise 7.5% to $5.3 
** Co receives FDA clearance for its Trinav Advance device, expanding its product portfolio delivering targeted treatments to the liver
** Co plans a limited market release of the device in the coming weeks
** Five brokerages rate the stock "buy"; median PT is $9 - data compiled by LSEG
** Including session's move, stocks down 29.4% YTD

(Reporting by Anand Gopal in Bengaluru)
((AnandGopal.R@thomsonreuters.com))